Session (CTI)

The session will begin with a brief overview of the evolving global health policy landscape, highlighting how recent changes in the U.S. and internationally may reshape the role of Europe, Japan, and Canada in pharmaceutical R&D and innovative launches, while increasingly treating medicines as tradable goods rather than products assessed through HTA frameworks. A moderated discussion will then explore the challenges of generating evidence in fragmented regulatory environments, the strategic balance between pricing optimization and value creation, and the impact of uncertainty on capital allocation and market prioritization. The session will feature perspectives from pharma experts and conclude with audience engagement on how these forces may shape the future of pharmaceutical innovation, affordability, and patient access.